Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy ...

Praxis Gets FDA Breakthrough Designation for Essential Tremor Drug

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.
Seeking Alpha

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary ...
Benzinga.com

Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug

Praxis Precision Medicines Inc. (NASDAQ: PRAX) stock rose Monday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for ulixacaltamide for essential ...
ksn.com

Praxis Precision Medicines Announces Plans to Begin Ulixacaltamide Phase 3 in Essential Tremor by Year End After Completing End of Phase 2 Meeting with FDA

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...
Seeking Alpha

Praxis Precision Medicines to Present Analyses of Patient-Focused, Clinically Meaningful Endpoints from Essential1 Study of Ulixacaltamide in Essential Tremor at the 2023 MDS ...

BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines (PRAX), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of ...
Business Insider

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA in ...
Insider Monkey

Praxis Precision Medicines Reports Positive Phase 3 Results for Ulixacaltamide in Essential Tremor

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the Reddit stocks that will go to the moon. On October 16, Praxis Precision Medicines announced positive topline results for its pivotal Phase 3 ...
MarketWatch

Praxis Precision Shares Soar on Phase 3 Essential Tremor Success

Praxis Precision Medicines shares more than doubled in premarket trading Thursday after the clinical-stage biopharmaceutical reported positive topline results from a pair of late-stage studies of its ...
Taiwan News

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX)

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the 20 Best Performing Stocks in 2025. On January 5, 2026, TheFly ...